Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 722-727

  Farhat, Fadi S ^a,b,c   Kattan, Joseph ^b,d   Chahine, Georges Y ^b,d   Younes, Fariha C ^d   Nasr, Fadi L ^b,d   Mroue, Raghda M ^c   Ghosn, Marwan G ^b,d  

^a MOUNT LEBANON HOSPITAL   (Lebanon)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

^c Hammoud Hospital   (Lebanon)

^d Cancer Research Group Collaborative Group   (Lebanon)

Author keywords

Capecitabine; Gastric cancer; Irinotecan; Low dose; Metastatic; Phase II study

Indexed keywords

CAPECITABINE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GASTRECTOMY; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PALLIATIVE CARE; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS;

EID: 77956937509     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9275-z     Document Type: Article

References (32)

1. JY Tsai H Safran 2003 Status of treatment for advanced gastric carcinoma Curr Oncol Rep 5 210 218 10.1007/s11912-003-0112-9 12667418
2. S Wöhrer M Raderer M Hejna 2004 Palliative chemotherapy for advanced gastric cancer Ann Oncol 15 1585 1595 10.1093/annonc/mdh422 15520058 (Pubitemid 39567288)
3. A Cervantes S Roselló D Roda E Rodríguez-Braun 2008 The treatment of advanced gastric cancer: current strategies and future perspectives Ann Oncol 19 Suppl 5 v103 v107 10.1093/annonc/mdn321 18611865
4. AD Wagner, et al. 2006 Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903 2909 10.1200/JCO.2005.05.0245 16782930 1:CAS:528:DC%2BD28XntV2gs7s%3D (Pubitemid 46630593)
5. Kyoto Research Group for Chemotherapy of Gastric Cancer 1992 A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin 4-epirubicin (FPEPIR) Anticancer Res 12 1983 1988
6. JS Waters, et al. 1999 Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Br J Cancer 80 269 272 10.1038/sj.bjc.6690350 10390007 1:CAS:528:DyaK1MXjtFyksbo%3D (Pubitemid 29210117)
7. P Ross, et al. 2002 Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 1996 2004 10.1200/JCO.2002.08.105 11956258 1:CAS:528: DC%2BD38XjvVKmsrw%3D (Pubitemid 34413593)
8. A Roth, et al. 1999 High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study Tumori 85 234 238 10587023 1:CAS:528:DC%2BD3cXht1alt7w%3D
9. A Bamias, et al. 1996 Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival Cancer 77 1978 1985 10.1002/(SICI)1097- 0142(19960515)77:10<1978::AID-CNCR3>3.0.CO;2-D 8640659 1:CAS:528:DyaK28XjtFGrsLs%3D (Pubitemid 26142038)
10. A Webb, et al. 1997 Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261 267 8996151 1:CAS:528: DyaK2sXnsV2msA%3D%3D
11. D Cunningham, et al. 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46 10.1056/NEJMoa073149 18172173 1:CAS:528:DC%2BD1cXisFSktg%3D%3D
12. E Van Cutsen, et al. 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997 10.1200/JCO.2006.06.8429 1:CAS:528:DC%2BD28Xht1GnurzJ (Pubitemid 46631401)
13. O Bouché, et al. 2004 Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803 J Clin Oncol 22 4319 4328 10.1200/JCO.2004.01.140 15514373 1:CAS:528:DC%2BD2cXhtVKju7fP (Pubitemid 41199650)
14. M Moehler, et al. 2005 Randomized phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer Br J Cancer 92 2122 2128 10.1038/sj.bjc.6602649 15942629 1:CAS:528:DC%2BD2MXltVygtbc%3D (Pubitemid 40973775)
15. M Dank, et al. 2005 Randomized phase III trial of irinotecan (CPT11) 5-FU/folinic acid (FA) vs CDDP-5-FU in first line advanced gastric cancer patients J Clin Oncol 23 308 (Abstr 4003)
16. F Farhat 2007 A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer Med Oncol 24 137 146 10.1007/BF02698032 17848736 1:CAS:528:DC%2BD2sXpsVKls7w%3D (Pubitemid 350139221)
17. N Boku, et al. 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319 323 10458249 1:CAS:528:DyaK1MXltVyrtg%3D%3D
18. S Shimada Y Yagi M Kuramoto N Aoki M Ogawa 2003 Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil Oncol Rep 10 687 691 12684644 1:CAS:528:DC%2BD3sXjsVOltL0%3D
19. CH Kohne, et al. 2003 Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial Br J Cancer 89 997 1001 10.1038/sj.bjc.6601226 12966415 1:CAS:528:DC%2BD3sXntVKgu7k%3D (Pubitemid 37239201)
20. Cunningham D, et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol. 2006;24(18S):LBA4017 (2006 ASCO Annual Meeting Proceedings).
21. M Moehler, et al. 2003 Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer Anticancer Drugs 14 645 650 10.1097/00001813-200309000-00010 14501387 1:CAS:528:DC%2BD3sXntlKjtrs%3D (Pubitemid 37303932)
22. A Bamias D Papamichael K Syrigos N Pavlidis 2003 Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer J Chemother 15 275 281 12868555 1:CAS:528:DC%2BD3sXmtFSqurk%3D
23. T Yoshioka, et al. 2003 Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer Gastric Cancer 6 153 158 10.1007/s10120-003-0244-5 14520528 1:CAS:528: DC%2BD3sXns1GqurY%3D (Pubitemid 37229061)
24. C Pozzo, et al. 2004 Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study Ann Oncol 15 1773 1781 10.1093/annonc/mdh473 15550582 1:STN:280: DC%2BD2crotVGitw%3D%3D (Pubitemid 40017161)
25. W Koizumi, et al. 2003 A pilot phase II study of capecitabine in advanced and recurrent gastric carcinoma Oncology 64 232 236 10.1159/000069313 12697963 1:CAS:528:DC%2BD3sXivFOhtrg%3D (Pubitemid 36438808)
26. J Ajani 2006 Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers Cancer 107 221 231 10.1002/cncr.21986 16770784 1:CAS:528:DC%2BD28Xnsl2mt7Y%3D (Pubitemid 44043103)
27. JH Baek, et al. 2006 Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer Br J Cancer 94 1407 1411 10.1038/sj.bjc.6603093 16641916 1:CAS:528:DC%2BD28XksFKntLg%3D (Pubitemid 43772274)
28. ME Burge, et al. 2006 A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma Br J Cancer 94 1281 1286 10.1038/sj.bjc.6603084 16622464 1:CAS:528:DC%2BD28XktVahtrg%3D
29. SC Oh, et al. 2007 A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer Br J Cancer 96 1514 1519 10.1038/sj.bjc.6603752 17473829 1:CAS:528:DC%2BD2sXlt1Kmtbs%3D (Pubitemid 46762953)
30. P Rougier, et al. 1994 Neoadjuvant chemotherapy in locally advanced gastric carcinoma-a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum Eur J Cancer 30A 9 1269 1275 10.1016/0959-8049(94)90171-6 7999411 1:STN:280:DyaK2M%2Fpt1ektg%3D%3D (Pubitemid 24322060)
31. JA Wils, et al. 1991 Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group J Clin Oncol 9 827 831 2016625 1:STN:280:DyaK3M3gt1ajuw%3D%3D
32. D Kelsen, et al. 1992 FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer J Clin Oncol 10 541 548 1548519 1:STN:280:DyaK387ptl2lsw%3D%3D